- Stocks
- Healthcare
- NASDAQ: EDIT

Price (delayed)

$7.46

Market cap

$514.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.21

Enterprise value

$416.94M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a

The debt has soared by 106% from the previous quarter and by 67% YoY

Editas Medicine's quick ratio has decreased by 46% YoY and by 41% QoQ

What are the main financial stats of EDIT

Market
Valuations
Earnings

Shares outstanding

68.97M

Market cap

$514.52M

Enterprise value

$416.94M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.42

Price to sales (P/S)

25.99

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

21.15

Revenue

$19.71M

EBIT

-$224.66M

EBITDA

-$218.32M

Free cash flow

-$181.45M

Per share
Balance sheet
Liquidity

EPS

-$3.21

Free cash flow per share

-$2.64

Book value per share

$5.25

Revenue per share

$0.29

TBVPS

$7.49

Total assets

$514.32M

Total liabilities

$153.64M

Debt

$43.95M

Equity

$360.68M

Working capital

$296.64M

Debt to equity

0.12

Current ratio

5.94

Quick ratio

5.81

Net debt/EBITDA

0.45

Margins
Efficiency
Dividend

EBITDA margin

-1,107.5%

Gross margin

100%

Net margin

-1,118.3%

Operating margin

-1,146.3%

Return on assets

-39.2%

Return on equity

-50.3%

Return on invested capital

-62%

Return on capital employed

-49.5%

Return on sales

-1,139.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Editas Medicine stock price performed over time

Intraday

0.54%

1 week

-10.87%

1 month

-17.66%

1 year

-60.63%

YTD

-15.9%

QTD

-15.9%

How have Editas Medicine's revenue and profit performed over time

Revenue

$19.71M

Gross profit

$19.71M

Operating income

-$225.95M

Net income

-$220.43M

Gross margin

100%

Net margin

-1,118.3%

EDIT's operating margin has dropped by 52% year-on-year and by 44% since the previous quarter

The net margin has contracted by 48% YoY and by 43% from the previous quarter

The revenue has declined by 23% since the previous quarter and by 23% year-on-year

Editas Medicine's gross profit has decreased by 23% from the previous quarter and by 23% YoY

What is Editas Medicine's growth rate over time

What is Editas Medicine stock price valuation

P/E

N/A

P/B

1.42

P/S

25.99

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

21.15

EDIT's EPS is down by 13% year-on-year and by 9% since the previous quarter

EDIT's P/B is 71% below its 5-year quarterly average of 4.9 and 29% below its last 4 quarters average of 2.0

EDIT's equity is down by 35% year-on-year and by 13% since the previous quarter

The P/S is 51% less than the 5-year quarterly average of 52.7 and 26% less than the last 4 quarters average of 34.9

The revenue has declined by 23% since the previous quarter and by 23% year-on-year

How efficient is Editas Medicine business performance

The ROE has plunged by 56% YoY and by 22% from the previous quarter

Editas Medicine's ROA has decreased by 49% YoY and by 18% from the previous quarter

EDIT's return on sales is down by 49% year-on-year and by 42% since the previous quarter

EDIT's return on invested capital is down by 32% year-on-year and by 17% since the previous quarter

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

How did Editas Medicine financials performed over time

Editas Medicine's quick ratio has decreased by 46% YoY and by 41% QoQ

The current ratio has contracted by 45% YoY and by 41% from the previous quarter

The debt is 88% less than the equity

The company's debt to equity has surged by 140% QoQ and by 140% YoY

The debt has soared by 106% from the previous quarter and by 67% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.